Bristol-Myers Squibb and CytomX sign a $1.24 billion agreement to develop novel antibody therapies
-
Last Update: 2014-05-28
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Biovalley, May 27, 2014 / bioun / -- Bristol Myers Squibb (BMS) and cytomx therapy Co., Ltd jointly announced on May 27, 2014 that they have signed a global research cooperation and authorization agreement to discover, develop and commercialize the proprietary protobody of cytomx A novel therapy developed by antibody platform targeting several immune oncology targets Probody is a kind of completely recombined monoclonal antibody Its antigen binding sites are blocked by patented antibody masking technology, and remain inert in healthy tissues In tumor microenvironment, probody can be cut by tumor specific protease to be selectively activated, exposing the antigenic binding sites Probody focuses on the activity of therapeutic antibodies to tumors and is harmless to healthy tissues Probody's unique selectivity has expanded the therapeutic window of proven and novel targets, and is expected to create a new kind of more safe and effective therapy Under the terms of the agreement, cytomx grants Bristol Myers Squibb probodies the global exclusive right to develop and commercialize four oncology targets, including CTLA-4, a clinically proven immunosuppressive checkpoint receptor Bristol Myers Squibb will pay US $50 million in advance If all four targets reach development, regulatory and sales milestones, cytomx will receive milestone payments of nearly $1.2 billion, as well as royalties for product sales.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
